Anika Therapeutics announces Monovisc PMA news Anika Therapeutics announced that it has received correspondence from the Chief Scientific Officer of the Center for Devices and Radiological Health of the U.S. FDA upholding the non-approvable decision for the Monovisc PMA that was previously disclosed. The company had utilized the FDA’s appeal process to continue to discuss the Monovisc PMA with the FDA.
News For ANIK From The Last 14 Days
Check below for free stories on ANIK the last two weeks.
